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Abstract
Purpose: Because of its rarity in any oncology centre, the clinical trends of male breast cancer specific to its geographical distri-
bution have remained relatively unexplored. This study was done to analyze the clinico-pathological data, treatment given and
survival patterns of male breast cancer patients visiting our tertiary medical centre and compare our results with available liter-
ature.Methods: All male breast cancer patients registered at our clinic from 2003 to 2009 were included. Frequency distribution
analysis of the demographic and clinico-pathological data and treatment variables was done. Treatment outcome was examined
from Kaplan-Meir survival estimates. Results: Thirty-three male breast cancer patients were encountered. The median age of
presentation was sixty years. Mostly (87.9%) they presented with lump in breast or axilla and were clinically staged to be ‘3’
(57.6%).Obesity and alcohol were the commonest risk factors identified. Modified radical mastectomy was the commonest
(69.6%) definitive therapy rendered with (only for clinically staged 3 patients) or without neo-adjuvant chemotherapy. Infil-
trating ductal carcinoma was identified in most cases. Twenty-two patients received adjuvant chemotherapy and twenty-four
received adjuvant radiotherapy. Eighteen (54.5%) patients were hormone-receptor positive and received tamoxifen. The medi-
an Overall survival (OS) and Progression-free survival (PFS) came out to be 14.3 months (standard error, SE of 1.185; 95% con-
fidence interval, CI 12-16.6) and 15.7 (SE 5.35, 95% CI 5.2-26.19) months respectively. Conclusion: Male breast cancers usually
carry a poor prognosis due to presentation at later stages. Most of our results correlate with previous literature. Multi-centric
prospective studies are required to validate the etiological factors and prognostic determinants of survival.
Keywords:Male Breast Cancer; Rare; Advanced Stage; Poor Outcome
Introduction
Male Breast Cancer (MBC) is a relatively rare entity 1 ac-
counting for less than 1% of all breast cancers and 1% of all
malignancies in men.2The Cancer Statistics, 2013 3 gives an
estimate of 2240 new MBC cases to be diagnosed and 410
deaths to occur from the same by 2013 in US population. The
mean age at diagnosis is 67 years (between 60 to 70 years)
which is 5 years older than that in women 1 in US, but in
other parts of the world such as the Middle East and South
Asia, the age gap is smaller.4, 5 As in women, breast cancer in
males is also on the rise, the incidence has climbed 26% over
the past 25 years.1 The incidence of MBC in Northwest Eu-
rope and North America is approximately 1/100,000. 6
Genetic contributors to the risk of male breast cancer are
similar, but not identical to those in women. Family history
is relevant for both sexes 7, 8, and BRCA2 mutations and re-
arrangements play a particularly prominent role in male
breast cancer.9,10,11 Conditions that alter the ratio of estrogen
to androgen have been linked to breast cancer risk in men.
Klinefelter’s syndrome, exogenous estrogen or testosterone
use, obesity and a history of prostate cancer treated with
estrogens have been implicated.12-16
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Tumor biology and clinic behaviour of MBC have been re-
ported to closely correlate with breast cancers in women.
Majority of MBCs are of infiltrating ductal histology 12 and
are estrogen receptor positive.17 Most commonly they pre-
sent with lump in breast 18,19with positive axillary nodes.20,21
As in women, MBC survivorship is highly dependent on
grade of tumors with grade 3 fairing much poorly than lower
grades.21 Modified radical mastectomy has been recom-
mended to be the standard of care. Post mastectomy Radio-
therapy (PMRT) has been reported to prolong PFS 22 and
Local Recurrence free survival 23, while systemic therapy has
resulted in better outcomes in the node-positive patients.24
Tamoxifen therapy has been associated with improved re-
currence free survival.24
In this retrospective study we have tried to analyze the de-
mographic pattern and clinico-pathological characteristics of
MBC in the Indian scenario. Considering the inter-play of
prognostic determinants, how far the standard recommenda-
tions for management of MBC optimally affect survival in
the Indian context has been our special point of interest.
Methods and Materials
A thorough search of the patients’ registration records from
December 2003 to December 2009 was undertaken to iden-
tify the male breast cancer patients. Data on patient history,
relevant risk factors, presenting symptoms and signs, tumor
pathology, clinical and/or pathological stage, treatment of-
fered, details on recurrences were obtained from the patient
case records.
TNM staging was done according to the 6th American Joint
Committee on Cancer (AJCC) classification. Diagnosis was
done by fine needle aspiration cytology (FNAC) and/or from
biopsy specimen. Mammography was not done in our study.
Metastatic work-up included chest X-ray, ultrasonography of
abdomen and bone scan and was done in almost all cases
before definitive or adjuvant therapy was administered.
Hormone receptor assay was done by immu-
no-histochemistry (IHC). Neo-adjuvant or adjuvant chemo-
therapy with appropriate pre-medications was administered
and radiotherapy was given by Cobalt-60 machine. Tamoxi-
fen was prescribed to hormone receptor positive patients in a
dose of 20 mg per oral daily for five years after adjuvant
chemotherapy was completed.
After treatment completion, the patients were followed-up
at three monthly basis till death or December 2012. Thor-
ough clinical examination and imaging as and when required
were done at each visit. Relevant data on time of occurrence
and location of recurrences during this period were noted.
Frequency distribution tables and Kaplan - Meir estimates of
survival were analysed by SPSS statistics software Version
20.0 compatible with Windows 7 edition.
Results
Thirty-three male breast cancer patients were treated in our
institution from December 2003 to December 2009. The
median age at diagnosis was sixty years (range, 45-71 years).
The clinical presentations were most commonly
self-detected lump in the breast (twenty-nine patients,
87.9%) or axilla (fifteen patients, 45.5%), with or without
pain. Nipple retraction and skin ulceration were found in
33.3% and 12.1% of the patients respectively. The lump was
most commonly detected in the central quadrant (39.3%)
and the right breast (63.6%) was more affected than the left.
There were two patients who had undergone mastectomy
earlier without any other treatment and presented with
chest wall recurrence.
The risk factors commonly identified were obesity, high
alcohol consumption in last three decades and gynaecomas-
tia. The distribution of clinical presentations and risk factors
among the patients are shown in Table 1.
The patients most commonly presented in clinical stage 3
(57.6%).Tissue biopsy ( trucut or operative specimen) re-
vealed modified Bloom Richardon score 3 in the majority
(60.6%); ER/PR hormone receptor positivity was found in
54.5% patients while seven patients had triple negative sta-
tus. Almost all the cases were histopathologically Infiltrative
Ductal Carcinoma. The pathological stage 3 was commonly
(48.5%) observed and lymph node positivity in surgical
specimen was mostly between 1- 3 nodes (30.3%). Table 2
enlists these observations.
Primary treatment consisted of surgery. Modified radical
mastectomy was done most commonly (69.6 %), two patients
who presented with chest wall recurrence underwent toilet
mastectomy. Four patients with metastatic presentation re-
ceived no surgery. As per our institutional protocol, ‘clini-
cally staged 3’ patients received neo-adjuvant chemotherapy
(NACT) with either FAC (5-Fluorouracil, Adriamycin and
Cyclophosphamide) or TAC (Docetaxel, Adriamycin and
Cyclophosphamide) regimes. Clinically ‘staged 1 or 2’ pa-
tients (30.3%) were operated upfront. The median duration
for NACT was 69 days (standard deviation, SD-36 days) for
two to three cycles. Patients with clinical stage 4 disease
received upfront palliative chemotherapy with FAC regime
(two patients) or Docetaxel alone (two patients), for a mean
duration of 96 days (range 71-129 days). Two patients did
not receive any form of therapy due to poor performance
status (ECOG ≥ 3).
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TABLE 1: Clinical presentation and Risk factors.
Clinical presentation No. of patients (out of 33) %
Self detected lump in breast 29 87.9
Self-detected lump in axilla 15 45.5
Pain 25 45.5
Nipple retraction 11 33.3
Skin ulceration 4 12.6
Mastectomy done earlier 2 6.0
Laterality:
Right 21 63.6
Left 12 36.3
Location:
Upper outer quadrant 7 21.2
Upper inner quadrant 3 9.0
Lower outer quadrant 6 18.1
Lower inner quadrant 4 12.1
Central quadrant 13 39.3
Risk Factors:
Obesity 14 42.4
Heavy alcohol consumption 15 45.5
Gynaecomastia 2 6
Family history 2 6
Previous radiation exposure 1 3
Klinefelter’s syndrome 0 0
Occupational exposure 2 6
Prostate cancer 4 12.1
TABLE 2: Clinical Stage and Histopathology
In the adjuvant setting, only the two patients who under-
went toilet mastectomy received docetaxel; rest (66.6%)
were treated with FAC regime. The mean duration for adju-
vant chemotherapy was 70 days (SD-2.2 days) for those who
received NACT and 127 days (SD-2.2 days) when no NACT
was administered. Twenty-four (72.7%) patients received
adjuvant radiotherapy to a dose of 50 Gray in 25 fractions
(conventional fractionation) by Cobalt-60 machine. Hor-
mone therapy consisted of tamoxifen alone and was given to
in receptor positive status (54.5%). Salvage orchiectomy was
done in two patients. The above described treatment varia-
bles, lymph node harvest and pathological stage are summa-
rized in Table 3.
Clinical Stage No. of patients(out of 33) %
1 2 6.1
2 8 24.2
3 19 57.6
4 4 12.1
HISTOPATHOLOGY
Bloom Richardson grade :
1 2 6.1
2 8 24.2
3 20 60.6
Missing 3 9.1
Hormone receptor positivity:
ER/ PR +, Her2 neu - 18 54.5
ER/ PR -, Her2 neu + 3 9
ER/ PR - ,Her2 neu - 7 21.2
ER/PR+ ,Her2 neu + 0 0
Receptor status unknown 5 15.2
Histologic type:
IDC 31 93.9
Padget’s disease 2 6
Others 0 0
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TABLE 3: Treatment Variables and Pathological Staging
TREATMENT VARIABLES No. of patients (out of 33) %
Modified Radical mastectomy 23 69.6
Radical mastectomy 2 6
Toilet mastectomy 2 6
Orchiectomy 2 6
NACT-FAC regime 13 39.4
NACT-TAC regime 4 12.1
Upfront Palliative CT(FAC regime) 2 6
Upfront palliative CT(Docetaxel) 2 6
Adjuvant CT-FAC regime 22 66.6
Adjuvant CT- Docetaxel 2 6
Adjuvant RT 24 72.7
No treatment received 2 6
Pathological lymph nodes positive:
Nil 3 9.1
1-3 10 30.3
4-10 6 18.2
>10 6 18.2
Missing 8 24.2
Pathological stage:
1 1 3
2 8 24.2
3 16 48.5
4 4 12.1
Missing 4 12.1
TABLE 4: Pathological Stage Specific Over-all Survival (OS) and Progression-Free Survival (PFS):
* = Stage wise median progression free survival
The median follow-up period was seven months (SD -10.4
months), ranging from zero to thirty-six months. The recur-
rences were mostly distal-lung (8 patients, 24.2%) followed
by liver (5 patients, 15.1%), bone (2 patients, 6%) and brain
(1 patient). Local recurrence was observed in 2 (6%) patients.
Most (12 patients, 61.1%) of the recurrences occurred in the
first year of follow-up. The median over-all survival (OS)
and Progression-free survival (PFS) came out to be 14.3
months (standard error, SE of 1.185; 95% confidence inter-
val, CI 12-16.6) and 15.7 months (SE 5.35, 95% CI 5.2-26.19)
respectively. The stage specific OS and PFS are shown in
Table 4 and graphically represented by Kaplan –Meir curves
in Figure 1 and 2.There were significant differences in OS
(log rank test = 0.00) and PFS (log rank test = 0.02) between
different pathological stages.
Discussion
Our study corroborates with the theory that MBC has a peak
incidence 5-10 years later than that in females, since the
highest risk of breast cancers in females in India is between
45-50 years. The concept of smaller age gap in South Asian
scenario 4, 5, is however not supported by this study.
15-20% MBC patients have a positive family history of breast
cancer in a first degree relative.7,8 We found two patients
(6%) who had sisters with breast cancers. However the study
by Hill et al 25 on family history in MBC showed that it was
not associated with mean age at onset for the men nor was it
associated with survival. An abnormal oestrogen to androgen
ratio is also a known risk factor for the disease. Klinefelter’s
syndrome 13, exogenous oestrogen 14, obesity 15,16 and a his-
tory of prostate cancer 26 are all associated with this hormo-
nal imbalance. Also, prior exposure to radiation or elec-
tro-magnetic fields 27 and occupational exposure to volatile
aromatic hydrocarbons 28 contribute to the risk. This study
agrees with this view, with special emphasis on obesity and
heavy alcohol consumption 29 as the commonest risk factors
found in more than 40% of our patients. Risk estimates of
the association between gynecomastia and MBC are unstable
OS
(months)
PFS
(months)
Stage Median OS Std. error Confidence interval Median PFS Std error Confidence Interval
1 36.2 * 36.2 *
2 32.9 7.77 17.85-48.14 30.53 3.82 23.03-38.02
3 14.2 1.242 11.76-16.63 11.2 0.687 9.85-12.54
4 5.46 0.12 5.22-5.69 5.46 * 0.12 * 5.22-5.69 *
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due to the small sample sizes available. A recent European
case-control study of 74 MBC cases and 1,432 popula-
tion-based controls 29 observed a significant elevation in risk
for MBC associated with gynecomastia. We had two patients
(6%) with gynaecomastia in this study.
Inherited mutations and rearrangements of BRCA gene in-
crease the risk of MBC, more so with BRCA 2 (5-15%) than
BRCA 1 (less than 5%).8,10Data are mixed regarding the rel-
evance of other germ-line mutations such as those in PALB2,
the androgen receptor (AR), CYP17, and CHEK2. 30-32 Ge-
netic testing for any of these mutations was not done in any
of our patients.
Consistent with previous literature 18,19, the most common
presentation was a painless sub-areolar lump detected in
87.9% of our patients. The most common location in women
is the upper outer quadrant. This gender differences is likely
due to the paucity of breast tissue in males compared to the
females.1Nipple involvement and lymph node positivity 20,21
has been reported to be more common with MBC than fe-
male breast cancers. In our study, eleven (33.3%) patients
presented with nipple retraction and fifteen (45.5%) with
axillary lump.
The staging of MBCs follows the same TNM classification as
in women. The high propensity of lymph node metastasis
has been attributed to the later stages of presentation of
MBCs compared to the female counterparts. More than 50%
of MBCs are diagnosed at stage 3 and beyond.1 Consistent
with this observation, our patients most commonly (57.6%)
presented in stage 3. Breast conservation surgery is usually
not advocated in MBCs due to the inadequacy of breast tissue
and MRM has been recognised to be the standard proce-
dure.22,33 Twenty-nine (69.6%) of the patients of our study
underwent MRM as the curative surgery.
Majority of MBCs have infiltrating ductal type histology.26
Other histologies like ductal carcinoma in situ(DCIS), lobu-
lar carcinoma in situ(LCIS), mixed ductal and cribriform,
Paget’s disease, inflammatory, etc have been reported in
literature. Almost all (93.9%) of our patients had infiltrating
ductal histopathology. Consistent with the reports of MBCs
being usually hormone receptor positive 17, eighteen patients
(54.5%) in this study were found to have both estrogen and
progesterone receptors(ER, PR) by IHC. Recent studies 34
have shown lower rates of Her2neu positivity (2-15%) in
men than in women (18-20%). Her2neu positivity was found
in three patients and triple negative status in seven patients
of our study. Lymph nodal involvement is tightly linked to
breast cancer outcomes in men.16, 35-37 Lymph nodal harvest
between one to three was commonly (30.3%) observed in
our study. Smaller studies 38 have demonstrated the feasibil-
ity of sentinel node biopsy, but it is yet to receive standard
recommendation. So it was not performed in any of our pa-
tients.
FIG. 1: Pathological Stage Specific Kaplan-Meir estimates of over-all survival.
Test of equality of survival distributions for the different levels of pathological stage by Log-rank test = 0.00(significant)
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FIG. 2: Pathological Stage Specific Kaplan-Meir estimates of Progression-Free Survival
Test of equality of survival distributions for the different levels of pathological stage by Log-rank test = 0.02(significant).
With a specificity of 90% 22 mammography can aptly differ-
entiate between gynaecomastia and MBC.39 However the
rarity of this disease and the relative ease of diagnosis by
physical examination don’t support routine mammographic
screening. Also, most of the patients presented with palpable
tumors at presentation. For these two reasons, mammogra-
phy was not used in our study.
Neo-adjuvant chemotherapy is not yet the standard protocol
for locally advanced MBCs. However, we have used it for
clinical stage 3 patients as an extrapolation of data from fe-
male breast cancers as per our institutional protocol. Data on
adjuvant systemic chemotherapy are limited and whether it
significantly impacts survival is yet to be validated. Howev-
er, it has been associated with better outcomes in node posi-
tive patients.24, 40Two regimes- FAC and single agent docet-
axel have been used in this study. The choice of
neo-adjuvant (FAC or TAC regime) or adjuvant chemother-
apy was not validated and impact on survival not analyzed.
The impact of PMRT on PFS and L-RFS 23 prompted us to
use it to a total dose of 50 Gray in conventional fractionation
over five weeks, following the same indications followed in
female breast cancers. However, fewer numbers of patients
in previous studies 23 limits the substantiality of PMRT
translating to a survival benefit. Tamoxifen has been found
to prolong RFS 24 and it is the accepted standard of care for
receptor positive MBC. Hence, it was given to eighteen
(54.5%) of the patients with ER, PR positive status. Treat-
ment for metastatic disease in men has been primarily evalu-
ated in case reports and small case series. In a Spanish series
of fifty men with breast cancer, ten of whom were treated
with endocrine therapy for metastatic disease (either or-
chiectomy, estrogen, or tamoxifen), two of the ten had com-
plete responses, one of which lasted sixty months.41 Data
regarding use of aromatase inhibitors in conjunction with
gonadotropin releasing hormone agonist or orchiectomy to
achieve complete oestrogenic suppression is far too limited
to be accepted as a recommendation. None of the patients
received aromatase inhibitors. In our study palliative chem-
otherapy alone was offered to metastatic cases, upfront or
after recurrences.
Survival in MBCs has been chiefly reported based on grade
and stage of the disease. In forty-three Canadian patients 21,
5-year survival was 58% in those with grade 2 tumors and
45% in those with grade 3 tumors. Several studies 1,42, 43, 44
have consistently reported stage-specific 5-year OS of more
than 80% in stage 1, 50-80% in stage 2, 20-50% in stage 3
and 10% or less in stage 4 MBCs. As compared to females,
equivalent OS 1, 45 has been observed in age and
stage-matched patients, while disease specific survival was
significantly better in males 46 than in females. In our study,
at the end of 3 year follow-up, the median OS came out to be
36.9 months, 32.9 months, 14.2 months and 5.46 months for
pathological stages 1, 2, 3 and 4 respectively. Similar trend
was reported in progression-free survival also. Thus, the
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prognostic impact of stage was consistent with reported
trends of survival.
The analysis of the patterns of recurrences clearly shows that
distal recurrences fairly outnumber the local recurrences.
The most common site of distal recurrence was lung (24.2%)
followed by liver (15.1%). This proves the high propensity of
haematogeneous metastasis of MBC irrespective of the stage
of disease.
This study is representative of the scenario in eastern India.
The limitations of this study include small sample size, ret-
rospective data and single-institute experience. Also genetic
testing to detect genetic preponderances could not be done
due to financial inadequacy. Whether our institutional pro-
tocol for NACT in MBC positively impacts the outcome
needs to be validated by further studies. In short, we have
shown here that in our centre, the course of this disease and
outcome agrees mostly with other centres. However, the
search for newer treatment protocols to reduce the disease
burden and mortality still remains unanswered.
Conclusion
Although MBC has quite a number of similarities with fe-
male breast cancer, it can never be considered analogous to
the latter. The rarity of this disease delays the diagnosis and
patients usually present at later stages at our centre. This
confers a worse prognosis to all MBC patients in general.
Screening of patients with gynaecomastia for BRCA 2 gene
mutations may be contemplated if financial resources are
supportive. To conclude, in order to address the demograph-
ic variations of MBC and validate the impact of each prog-
nostic determinant, a bigger pooled data from a mul-
ti-institutional prospective study need to be analyzed.
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